Gilead Sciences: Harvoni Still Selling Like Hotcakes

Shares of Gilead Sciences (GILD) fell earlier this week when weak sales of Sovaldi spooked investors. New prescription data, however, shows “the downtick in Sovaldi being compensated by Harvoni,” says Citigroup’s Yaron Werber. He explains: AP/Paul Sakuma Following Harvoni’s (single pill regimen for hepC) approval on Oct 10th we expect a strong launch. During the [...]